324 related articles for article (PubMed ID: 31696332)
1. Novel Immunotherapy Combinations.
Bashir B; Wilson MA
Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
[TBL] [Abstract][Full Text] [Related]
2. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
3. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
Li J; Stanger BZ
Cancer Res; 2020 Oct; 80(19):4037-4041. PubMed ID: 32554552
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
[TBL] [Abstract][Full Text] [Related]
5. Emerging biomarkers for cancer immunotherapy in melanoma.
Axelrod ML; Johnson DB; Balko JM
Semin Cancer Biol; 2018 Oct; 52(Pt 2):207-215. PubMed ID: 28917578
[TBL] [Abstract][Full Text] [Related]
6. The future of cancer immunotherapy: microenvironment-targeting combinations.
Murciano-Goroff YR; Warner AB; Wolchok JD
Cell Res; 2020 Jun; 30(6):507-519. PubMed ID: 32467593
[TBL] [Abstract][Full Text] [Related]
7. Immune resilience in response to cancer therapy.
Gicobi JK; Barham W; Dong H
Cancer Immunol Immunother; 2020 Nov; 69(11):2165-2167. PubMed ID: 33011909
[No Abstract] [Full Text] [Related]
8. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
Olson DJ; Luke JJ
Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272
[No Abstract] [Full Text] [Related]
9. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Golay J; Andrea AE
Antibodies (Basel); 2020 May; 9(2):. PubMed ID: 32443877
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies for pediatric cancer: current landscape and future perspectives.
Hutzen B; Paudel SN; Naeimi Kararoudi M; Cassady KA; Lee DA; Cripe TP
Cancer Metastasis Rev; 2019 Dec; 38(4):573-594. PubMed ID: 31828566
[TBL] [Abstract][Full Text] [Related]
11. 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.
Fortis SP; Kotsakis A; Le Tourneau C; Tsitsilonis OE; Georgoulias V; Baxevanis CN
Cancer Immunol Immunother; 2019 Aug; 68(8):1391-1400. PubMed ID: 31309256
[No Abstract] [Full Text] [Related]
12. The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review.
Wang J; Li Z; Yin H
Ophthalmol Ther; 2024 May; 13(5):1103-1123. PubMed ID: 38498280
[TBL] [Abstract][Full Text] [Related]
13. Immuno-oncology combinations: raising the tail of the survival curve.
Harris SJ; Brown J; Lopez J; Yap TA
Cancer Biol Med; 2016 Jun; 13(2):171-93. PubMed ID: 27458526
[TBL] [Abstract][Full Text] [Related]
14. LAG-3 : recent developments in combinational therapies in cancer.
Chavanton A; Mialhe F; Abrey J; Baeza Garcia A; Garrido C
Cancer Sci; 2024 May; ():. PubMed ID: 38702996
[TBL] [Abstract][Full Text] [Related]
15. Run for your life: an integrated virtual tissue platform for incorporating exercise oncology into immunotherapy.
Serrano JA; Hagar A
Cancer Immunol Immunother; 2021 Jul; 70(7):1951-1964. PubMed ID: 33416943
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L; Elewaut A; Gerard CL; Umkehrer C; Leiendecker L; Pedersen M; Krecioch I; Hoffmann D; Novatchkova M; Kuttke M; Neumann T; da Silva IP; Witthock H; Cuendet MA; Carotta S; Harrington KJ; Zuber J; Scolyer RA; Long GV; Wilmott JS; Michielin O; Vanharanta S; Wiesner T; Obenauf AC
Nat Cancer; 2021 Jul; 2(7):693-708. PubMed ID: 35121945
[TBL] [Abstract][Full Text] [Related]
17. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
Lhuillier C; Vanpouille-Box C; Galluzzi L; Formenti SC; Demaria S
Semin Cancer Biol; 2018 Oct; 52(Pt 2):125-134. PubMed ID: 29258856
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015.
Pandha H; Pawelec G
Cancer Immunol Immunother; 2015 Sep; 64(9):1071-4. PubMed ID: 26267043
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies.
Dillon AB; Lin K; Kwong A; Ortiz S
AIMS Public Health; 2015; 2(1):86-114. PubMed ID: 29546098
[TBL] [Abstract][Full Text] [Related]
20. Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.
Ruggiero R; Stelitano B; Fraenza F; di Mauro G; Scavone C; Sportiello L; Rafaniello C; Di Napoli R; Danesi R; Del Re M; Rossi F; Capuano A
Front Oncol; 2022; 12():824511. PubMed ID: 35372076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
